TY - JOUR
T1 - Pulmonary arterial hypertension
T2 - Baseline characteristics from the REVEAL registry
AU - Badesch, David B.
AU - Raskob, Gary E.
AU - Elliott, C. Greg
AU - Krichman, Abby M.
AU - Farber, Harrison W.
AU - Frost, Adaani E.
AU - Barst, Robyn J.
AU - Benza, Raymond L.
AU - Liou, Theodore G.
AU - Turner, Michelle
AU - Giles, Scott
AU - Feldkircher, Kathy
AU - Miller, Dave P.
AU - McGoon, Michael D.
N1 - Funding Information:
Financial/nonfinancial disclosures: The authors have reported to CHEST the following conflicts of interest: Dr Badesch has served as a consultant for Actelion/CoTherix, Gilead/Myogen, Encysive Pharmaceuticals, Pfizer, GlaxoSmithKline, Lung Rx, United Therapeutics, Eli Lilly & Company/ICOS, Biogen Idec, and mondoBIOTECH. He has received grants from Actelion/CoTherix, Gilead/Myogen, Encysive Pharmaceuticals, Pfizer, United Therapeutics, Lung Rx, Eli Lilly & Company/ICOS, and NIH/NHLBI, and has received honoraria for his service on the REVEAL Steering Committee, which is supported by Actelion. Dr Barst serves as a consultant for and has received honoraria from Actelion, Bayer, GeneraMedix, Gilead, Eli Lilly & Company, MondoBIOTECH, and Pfizer. She has provided expert testimony on diet pill litigation for the plaintiffs and has also received grants from Actelion, GeneraMedix, Gilead, Eli Lilly & Company, NIH/NHLBI, Novartis, Pfizer, and United Therapeutics. She has received honoraria for her service on the REVEAL Steering Committee, which is supported by Actelion. Dr Benza has received honoraria from Actelion, United Therapeutics, and Gilead, and has received or is pending receipt of grants from Actelion, United Therapeutics, Gilead, and LungRx. He has received honoraria for his service on the REVEAL Steering Committee, which is supported by Actelion. Dr Elliott is employed by Intermountain Healthcare. Intermountain Healthcare, with Dr Elliott as Principal Investigator, has received grant support during the past 5 years from Actelion, Pfizer, Encysive, and United Therapeutics. Dr Elliott has received honoraria for his service on the REVEAL Steering Committee, which is supported by Actelion. Dr Farber serves as a consultant and is on the speaker's bureau for Actelion. He has received honoraria for his service on the REVEAL Steering Committee, which is supported by Actelion. Dr Feldkircher and Mr Giles are employed by Actelion Pharmaceuticals US, Inc. Dr Frost serves as a consultant for Gilead and Actelion. She has received honoraria from Gilead, Actelion, and Pfizer and has provided expert testimony on diet pill litigation. She has also received grants from Gilead and Actelion and grants to Baylor for IRB approved research. She also has received honoraria for her service on the REVEAL Steering Committee, which is supported by Actelion. Ms Krichman serves as a consultant for clinical research studies and advisory boards for Actelion, Gilead, United Therapeutics, GlaxoSmithKline, and GeneraMedix. She has also received honoraria for speaker bureau participation in PAH lectures for Actelion, Gilead, and United Therapeutics and has received educational grants and grants for investigator-initiated studies from United Therapeutics and GlaxoSmithKline. Dr Liou has received grants from the NIH/NHLBI, the Margolis Family Foundation of Utah, and the Cystic Fibrosis [CF] Foundation. He has been the site Principal Investigator for studies of CF and its treatment of the Therapeutic Development Network of the CF Foundation, for Altus, Axcan Scandipharm, Bayer, Boehringer, Genentech, Gilead, Inspire, Kalobios, MPEX, Novartis, and Vertex. He has received honoraria for his service on the REVEAL Steering Committee, which is supported by Actelion. Dr McGoon serves as a consultant with Actelion/CoTherix, Gilead/Myogen, Lung Rx, and Medtronic. He has received grants from Gilead/Myogen and Medtronic. He has received honoraria for his service on the REVEAL Steering Committee, which is supported by Actelion. Mr Miller and Ms Turner are employed by ICON Clinical Research, a company that receives research support from Actelion and other pharmaceutical companies. Dr Raskob serves as a consultant and receives honoraria from Actelion, Bayer, Bristol-Myers Squibb, Daiichi Sankyo, Inc., GlaxoSmithKline, Johnson & Johnson, Pfizer, sanofi-aventis, Takeda, TOPP, and Thrombogenics. He has received honoraria for his service on the REVEAL Steering Committee, which is supported by Actelion.
Funding Information:
Funding/Support: The REVEAL Registry is sponsored by Actelion Pharmaceuticals. Editorial support for the preparation of this manuscript was funded by Actelion Pharmaceuticals and provided by Jennifer M. Kulak, PhD, and Carol A. Lewis, PhD, from Wolters Kluwer.
Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2010/2/1
Y1 - 2010/2/1
N2 - Background: The Registry to EValuate Early And Long-term pulmonary arterial hypertension disease management (REVEAL Registry) was established to provide updated characteristics of patients with pulmonary arterial hypertension (PAH) and to improve diagnosis, treatment, and management. Methods: Fifty-four US centers enrolled consecutively screened patients with World Health Organization group I PAH who met expanded hemodynamic criteria of mean pulmonary arterial pressure (PAP) > 25 mm Hg at rest (30 mm Hg with exercise), pulmonary capillary wedge pressure (PCWP) ≤18 mm Hg, and pulmonary vascular resistance ≥ 240 dynes · s ·cm-5. Patients meeting the traditional hemodynamic definition (PCWP ≤15 mm Hg) were compared with those with a PCWP of 16 to18 mm Hg. Results: Between March 2006 and September 2007, 2,967 patients enrolled. Among 2,525 adults meeting traditional hemodynamic criteria, the mean age was 53 ±14 years, and 2,007 (79.5%) were women. The mean duration between symptom onset and diagnostic catheterization was 2.8 years, and1,008 (41.3%) patients were treated with more than one pulmonary vascular-targeted medication. Compared with patients meeting the traditional hemodynamic definition of PAH, patients with a PCWP of16 to18 mm Hg were older, more obese, had a lower 6-min walk distance, and had a higher incidence of systemic hypertension, sleep apnea, renal insufficiency, and diabetes. Conclusions: Patients in the REVEAL Registry are older and more often female than in previous descriptions. Delays between symptom onset and diagnostic catheterization persist. Many treatment regimens are fundamentally empirical, and data will be required to determine outcomes, improve risk stratification, and develop and validate more precise prognostic tools. Patients with PCWP of 16 to18 mm Hg differ in a number of important respects from those meeting the traditional hemodynamic definition of PAH.
AB - Background: The Registry to EValuate Early And Long-term pulmonary arterial hypertension disease management (REVEAL Registry) was established to provide updated characteristics of patients with pulmonary arterial hypertension (PAH) and to improve diagnosis, treatment, and management. Methods: Fifty-four US centers enrolled consecutively screened patients with World Health Organization group I PAH who met expanded hemodynamic criteria of mean pulmonary arterial pressure (PAP) > 25 mm Hg at rest (30 mm Hg with exercise), pulmonary capillary wedge pressure (PCWP) ≤18 mm Hg, and pulmonary vascular resistance ≥ 240 dynes · s ·cm-5. Patients meeting the traditional hemodynamic definition (PCWP ≤15 mm Hg) were compared with those with a PCWP of 16 to18 mm Hg. Results: Between March 2006 and September 2007, 2,967 patients enrolled. Among 2,525 adults meeting traditional hemodynamic criteria, the mean age was 53 ±14 years, and 2,007 (79.5%) were women. The mean duration between symptom onset and diagnostic catheterization was 2.8 years, and1,008 (41.3%) patients were treated with more than one pulmonary vascular-targeted medication. Compared with patients meeting the traditional hemodynamic definition of PAH, patients with a PCWP of16 to18 mm Hg were older, more obese, had a lower 6-min walk distance, and had a higher incidence of systemic hypertension, sleep apnea, renal insufficiency, and diabetes. Conclusions: Patients in the REVEAL Registry are older and more often female than in previous descriptions. Delays between symptom onset and diagnostic catheterization persist. Many treatment regimens are fundamentally empirical, and data will be required to determine outcomes, improve risk stratification, and develop and validate more precise prognostic tools. Patients with PCWP of 16 to18 mm Hg differ in a number of important respects from those meeting the traditional hemodynamic definition of PAH.
UR - http://www.scopus.com/inward/record.url?scp=76749135710&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=76749135710&partnerID=8YFLogxK
U2 - 10.1378/chest.09-1140
DO - 10.1378/chest.09-1140
M3 - Article
C2 - 19837821
AN - SCOPUS:76749135710
VL - 137
SP - 376
EP - 387
JO - CHEST
JF - CHEST
SN - 0012-3692
IS - 2
ER -